|
DE10238722A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
|
|
GT200500281A
(es)
*
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0500785D0
(en)
*
|
2005-01-14 |
2005-02-23 |
Novartis Ag |
Organic compounds
|
|
EA024006B1
(ru)
*
|
2006-02-02 |
2016-08-31 |
Миллениум Фармасьютикалз, Инк. |
Ингибиторы е1 активирующих ферментов
|
|
WO2007095536A2
(en)
*
|
2006-02-13 |
2007-08-23 |
Mount Sinai School Of Medicine |
Treatment and prevention of renal disease
|
|
GB0607950D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
EP2322525B1
(en)
*
|
2006-04-21 |
2013-09-18 |
Novartis AG |
Purine derivatives for use as adenosin A2A receptor agonists
|
|
GB0607945D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
GB0607948D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
GB0607953D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
GB0607944D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
EP1889846A1
(en)
|
2006-07-13 |
2008-02-20 |
Novartis AG |
Purine derivatives as A2a agonists
|
|
ZA200900670B
(en)
*
|
2006-08-08 |
2010-04-28 |
Millennium Pharm Inc |
Heteroaryl compounds useful as inhititors of E1 activating enzymes
|
|
US8008307B2
(en)
|
2006-08-08 |
2011-08-30 |
Millennium Pharmaceuticals, Inc. |
Heteroaryl compounds useful as inhibitors of E1 activating enzymes
|
|
EP1903044A1
(en)
*
|
2006-09-14 |
2008-03-26 |
Novartis AG |
Adenosine Derivatives as A2A Receptor Agonists
|
|
CL2007002994A1
(es)
*
|
2006-10-19 |
2008-02-08 |
Wyeth Corp |
Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
|
|
CA2669108A1
(en)
*
|
2006-11-10 |
2008-05-15 |
Novartis Ag |
Cyclopentene diol monoacetate derivatives
|
|
US7897737B2
(en)
|
2006-12-05 |
2011-03-01 |
Lasergen, Inc. |
3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
|
|
WO2008089329A2
(en)
|
2007-01-18 |
2008-07-24 |
President And Fellows Of Harvard College |
Novel activation and transfer cascade for ubiquitin
|
|
EP2178880B1
(en)
|
2007-08-02 |
2017-10-04 |
Millennium Pharmaceuticals, Inc. |
Process for the synthesis of e1 activating enzyme inhibitors
|
|
AU2013204618B2
(en)
*
|
2007-08-02 |
2015-11-05 |
Takeda Pharmaceutical Company Limited |
Process for the synthesis of E1 activating enzyme inhibitors
|
|
WO2009050199A1
(en)
*
|
2007-10-17 |
2009-04-23 |
Novartis Ag |
Purine derivatives as adenosine al receptor ligands
|
|
JP5498392B2
(ja)
|
2007-11-30 |
2014-05-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
KR101677772B1
(ko)
|
2008-06-11 |
2016-11-18 |
레이저젠, 인코퍼레이티드 |
뉴클레오타이드 및 뉴클레오사이드 그리고 시퀀싱에서의 이들의 이용 방법
|
|
JP5453431B2
(ja)
|
2008-09-08 |
2014-03-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
|
|
CN102369204A
(zh)
*
|
2008-09-26 |
2012-03-07 |
新加坡科技研究局 |
3-脱氮瓶菌素衍生物
|
|
PE20120505A1
(es)
|
2009-03-31 |
2012-05-09 |
Boehringer Ingelheim Int |
Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
|
|
EP2430026A1
(en)
|
2009-05-14 |
2012-03-21 |
Millennium Pharmaceuticals, Inc. |
Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
|
|
AR077859A1
(es)
|
2009-08-12 |
2011-09-28 |
Boehringer Ingelheim Int |
Compuestos para el tratamiento de trastornos del snc
|
|
AP2012006631A0
(en)
|
2010-08-12 |
2012-12-31 |
Boehringer Ingelheim Int |
6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
|
|
US8580762B2
(en)
|
2010-12-03 |
2013-11-12 |
Epizyme, Inc. |
Substituted purine and 7-deazapurine compounds
|
|
CA2819620A1
(en)
|
2010-12-03 |
2012-06-21 |
Epizyme, Inc. |
Modulators of histone methyltransferase, and methods of use thereof
|
|
EP2646454B1
(en)
|
2010-12-03 |
2015-07-08 |
Epizyme, Inc. |
7-deazapurine modulators of histone methyltransferase, and methods of use thereof
|
|
US20130040971A1
(en)
|
2011-02-14 |
2013-02-14 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
WO2012158789A2
(en)
|
2011-05-17 |
2012-11-22 |
St. Jude Children's Research Hospital |
Methods and compositions for inhibiting neddylation of proteins
|
|
JP6038150B2
(ja)
|
2011-08-24 |
2016-12-07 |
ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｎｅｄｄ８活性化酵素阻害剤
|
|
WO2013052814A2
(en)
*
|
2011-10-07 |
2013-04-11 |
Millennium Pharmaceuticals, Inc. |
E1 enzyme mutants and uses thereof
|
|
EP2771489B1
(en)
|
2011-10-28 |
2018-07-04 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to nae inhibitors
|
|
MY176125A
(en)
|
2011-11-03 |
2020-07-24 |
Takeda Pharmaceuticals Co |
Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
|
|
UA117095C2
(uk)
|
2011-12-22 |
2018-06-25 |
Аліос Біофарма, Інк. |
Нуклеозидна сполука або її фармацевтично прийнятна сіль
|
|
EP2814791A4
(en)
|
2012-02-17 |
2015-08-19 |
Millennium Pharm Inc |
PYRAZOLOPYRIMIDINYL INHIBITORS OF ACTIVATION ENZYME OF UBIQUITIN
|
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
|
WO2013188881A1
(en)
*
|
2012-06-15 |
2013-12-19 |
President And Fellows Of Harvard College |
Compounds, compositions and methods for treating or preventing neurodegenerative disorders
|
|
EP2879681A4
(en)
*
|
2012-08-03 |
2015-12-23 |
Millennium Pharm Inc |
INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
|
|
US20150284422A1
(en)
|
2012-08-10 |
2015-10-08 |
Epizyme, Inc. |
Inhibitors of protein methyltransferase dot1l and methods of use thereof
|
|
US9597348B2
(en)
|
2012-09-06 |
2017-03-21 |
Epizyme, Inc. |
Method of treating leukemia
|
|
WO2014055543A2
(en)
|
2012-10-01 |
2014-04-10 |
Millennium Pharmaceuticals, Inc. |
Biomarkers and methods to predict response to inhibitors and uses thereof
|
|
AU2013365926B9
(en)
|
2012-12-21 |
2019-01-17 |
Zenith Epigenetics Ltd. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
WO2014124458A1
(en)
*
|
2013-02-11 |
2014-08-14 |
The Regents Of The University Of California |
Compositions and methods for treating neurodegenerative diseases
|
|
WO2014145576A2
(en)
|
2013-03-15 |
2014-09-18 |
Northwestern University |
Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
|
|
US9738679B2
(en)
|
2013-03-15 |
2017-08-22 |
Epizyme, Inc. |
Methods of synthesizing substituted purine compounds
|
|
CA2923752A1
(en)
|
2013-05-14 |
2014-11-20 |
Millennium Pharmaceuticals, Inc. |
Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
|
|
CA2915838C
(en)
*
|
2013-06-21 |
2023-04-18 |
Zenith Epigenetics Corp. |
Bicyclic bromodomain inhibitors
|
|
EP3010918B1
(en)
|
2013-06-21 |
2018-08-15 |
Zenith Epigenetics Ltd. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
JP6378759B2
(ja)
|
2013-07-02 |
2018-08-22 |
ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｓｕｍｏ活性化酵素阻害剤として有用なヘテロアリール化合物
|
|
JP6542212B2
(ja)
|
2013-07-31 |
2019-07-10 |
ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． |
ブロモドメイン阻害剤としての新規キナゾリノン
|
|
EP3104706B1
(en)
|
2014-02-11 |
2022-03-23 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
|
NO3103802T3
(https=)
*
|
2014-06-24 |
2018-04-07 |
|
|
|
SG11201610476VA
(en)
|
2014-07-01 |
2017-01-27 |
Millennium Pharm Inc |
Heteroaryl compounds useful as inhibitors of sumo activating enzyme
|
|
EP3227281A4
(en)
|
2014-12-01 |
2018-05-30 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
|
HK1246273B
(en)
|
2014-12-01 |
2019-12-06 |
恒翼生物医药(上海)股份有限公司 |
Substituted pyridines as bromodomain inhibitors
|
|
EP3230277B1
(en)
|
2014-12-11 |
2019-09-18 |
Zenith Epigenetics Ltd. |
Substituted heterocycles as bromodomain inhibitors
|
|
HK1245247A1
(zh)
|
2014-12-17 |
2018-08-24 |
恒翼生物医药科技(上海)有限公司 |
溴结构域的抑制剂
|
|
US10189841B2
(en)
|
2015-11-20 |
2019-01-29 |
Forma Therapeutics, Inc. |
Purinones as ubiquitin-specific protease 1 inhibitors
|
|
TWI623316B
(zh)
*
|
2015-12-22 |
2018-05-11 |
Taiho Pharmaceutical Co Ltd |
Antitumor effect enhancer derived from pyrrolopyrimidine compound
|
|
CN106008394B
(zh)
*
|
2016-05-23 |
2018-12-04 |
中国人民解放军第二军医大学 |
巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途
|
|
CN106854208B
(zh)
*
|
2016-11-25 |
2019-04-09 |
成都柏睿泰生物科技有限公司 |
肿瘤抑制剂mln4924的合成方法
|
|
WO2018213258A1
(en)
*
|
2017-05-15 |
2018-11-22 |
Millennium Pharmaceuticals, Inc. |
Treatment of merlin-deficient tumors using nae inhibitors
|
|
EP3641545A4
(en)
|
2017-06-21 |
2021-02-24 |
Mitokinin, Inc. |
COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
|
|
EP3684363A4
(en)
|
2017-09-21 |
2021-05-12 |
Millennium Pharmaceuticals, Inc. |
CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDÉN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES
|
|
WO2019109016A1
(en)
|
2017-12-01 |
2019-06-06 |
Millennium Pharmaceuticals, Inc. |
Biomarkers and methods for treatment with nae inhibitors
|
|
CN110218179B
(zh)
*
|
2018-03-02 |
2020-08-04 |
新发药业有限公司 |
一种4-氨基-2-氯-3-硝基吡啶的制备方法
|
|
WO2020132603A2
(en)
*
|
2018-12-21 |
2020-06-25 |
Memorial Sloan-Kettering Cancer Center |
Salicyl-adenosinemonosulfamate analogs and uses thereof
|
|
AU2020256166A1
(en)
|
2019-04-02 |
2021-10-14 |
Aligos Therapeutics, Inc. |
Compounds targeting PRMT5
|
|
CN112079836B
(zh)
*
|
2019-06-13 |
2022-12-13 |
中国科学院上海药物研究所 |
三唑并嘧啶类化合物及其盐、组合物和应用
|
|
EP4319763A4
(en)
*
|
2021-04-09 |
2025-06-11 |
Emory University |
MODIFIED NUCLEOSIDES AND NUCLEOTIDE ANALOGUES AS ANTIVIRAL AGENT FOR CORONAVIRUS AND OTHER VIRUSES
|
|
WO2025059029A1
(en)
*
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating vexas syndrome
|
|
WO2025073926A1
(en)
*
|
2023-10-05 |
2025-04-10 |
Københavns Universitet |
An inhibitor of sumo e1-enzyme for use in tissue regeneration
|
|
CN117466965A
(zh)
*
|
2023-11-08 |
2024-01-30 |
湖南大学 |
一种合成碱基序列的方法
|
|
CN117466963A
(zh)
*
|
2023-11-08 |
2024-01-30 |
湖南大学 |
一种羟甲基的保护及脱保护方法
|
|
KR20250075265A
(ko)
*
|
2023-11-21 |
2025-05-28 |
한국화학연구원 |
Use1 활성을 억제하는 화합물 유도체, 및 이를 포함하는 암 예방 또는 치료용 약학 조성물
|
|
CN120737113B
(zh)
*
|
2025-09-03 |
2025-11-21 |
湖北师范大学 |
一种三唑并哒嗪类化合物区域选择性c3-h炔基化的方法
|